pharma Β· Hemophilia A Β· Hemophilia A or B With Inhibitors
Baxalta Innovations GmbH
Baxalta Innovations drug portfolio β 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 12 drugs and development assets β regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Baxalta Innovations drug portfolio β 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in Baxalta Innovations's portfolio. Mechanism: Somatic cell supplemental therapy.
Development asset linked to Baxalta Innovations in public FDA and regional records.
Development asset linked to Baxalta Innovations in public FDA and regional records.
Development asset linked to Baxalta Innovations in public FDA and regional records.
Development asset linked to Baxalta Innovations in public FDA and regional records.
Blood and blood forming organs (B02) compound in Baxalta Innovations's portfolio. Molecular target: Coagulation factor VIII.
Development asset linked to Baxalta Innovations in public FDA and regional records.
Blood and blood forming organs (B01) compound in Baxalta Innovations's portfolio. Molecular target: A disintegrin and metalloproteinase with thrombospondin motifs 13.
Development asset linked to Baxalta Innovations in public FDA and regional records.
Development asset linked to Baxalta Innovations in public FDA and regional records.
Development asset linked to Baxalta Innovations in public FDA and regional records.
Blood and blood forming organs (B02) compound in Baxalta Innovations's portfolio. Molecular target: von Willebrand factor.